TNFSF13B and autoimmune disease: Therapeutically, BAFF inhibitor belimumab has been shown to be effective in other autoimmune diseases (e.g. systemic Lupus Erythematous, SLE27), and recently case reports suggest it could be a valid third line treatment for refractory AIH patients28,29.